Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy

被引:245
作者
Henson, Elizabeth S. [1 ]
Gibson, Spencer B. [1 ]
机构
[1] Univ Manitoba, Manitoba Inst Cell Biol, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada
关键词
tryosine kinase receptors; EGF; cancer; apoptosis; survival; AKT; MAPK; STAT; death receptors; mitochondria; caspase; transcription factors; Bcl-2 family members;
D O I
10.1016/j.cellsig.2006.05.015
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
There is a balance between cell death and survival in living organisms. The ability of cells to sense their environment and decide to survive or die is dependent largely upon growth factors. Epidermal growth factor (EGF) is a key growth factor regulating cell survival. Through its binding to cell surface receptors, EGF activates an extensive network of signal transduction pathways that include activation of the PI3K/AKT, RAS/ERK and JAK/STAT pathways. These pathways predominantly lead to activation or inhibition of transcription factors that regulate expression of both pro- and anti-apoptotic proteins effectively blocking the apoptotic pathway. In cancer, EGF signaling pathways are often dysfunctional and targeted therapies that block EGF signaling have been successful in treating cancers. In this review, we will discuss the EGF survival signaling network, how it cross-talks with the apoptotic signaling pathways and the therapeutic drugs targeting the EGF survival pathway used to treat cancers. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:2089 / 2097
页数:9
相关论文
共 95 条
  • [1] ADAMS CW, 2005, CANCER IMMUNOL IMMUN, P1
  • [2] Monoclonal antibody therapy of cancer
    Adams, GP
    Weiner, LM
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (09) : 1147 - 1157
  • [3] Amann J, 2005, CANCER RES, V65, P226
  • [4] Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
    Amit-Vazina, M
    Shishodia, S
    Harris, D
    Van, Q
    Wang, M
    Weber, D
    Alexanian, R
    Talpaz, M
    Aggarwal, BB
    Estrov, Z
    [J]. BRITISH JOURNAL OF CANCER, 2005, 93 (01) : 70 - 80
  • [5] Inhibition of NF-κB sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance
    Anto, RJ
    Venkatraman, M
    Karunagaran, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (28) : 25490 - 25498
  • [6] Arlt A, 2002, INT J CLIN PHARM TH, V40, P336
  • [7] Role of tyrosine kinase inhibitors in cancer therapy
    Arora, A
    Scholar, EM
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) : 971 - 979
  • [8] Src family kinases and HER2 interactions in human breast cancer cell growth and survival
    Belsches-Jablonski, AP
    Biscardi, JS
    Peavy, DR
    Tice, DA
    Romney, DA
    Parsons, SJ
    [J]. ONCOGENE, 2001, 20 (12) : 1465 - 1475
  • [9] Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor α stimulation is counteracted by nuclear factor κB through c-FLIP-L expression
    Benoit, V
    Chariot, A
    Delacroix, L
    Deregowski, V
    Jacobs, N
    Merville, MP
    Bours, V
    [J]. CANCER RESEARCH, 2004, 64 (08) : 2684 - 2691
  • [10] Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria
    Blanco-Aparicio, C
    Pequeño, B
    Moneo, V
    Romero, L
    Leal, JFM
    Velasco, J
    Fominaya, J
    Carnero, A
    [J]. ANTI-CANCER DRUGS, 2005, 16 (09) : 977 - 987